Coherus Biosciences (CHRS) PT Raised to $25 at Citi
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.17 --0%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Join SI Premium – FREE
Citi raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $23.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta, Inc (OKTA) PT Raised to $235 at Truist Securities
- Camden Property Trust (CPT) PT Lowered to $108 at Truist Securities
- Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
